Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is characterized by progressive loss of lung function with high mortality within the first 5 years from diagnosis. In 2011–2014, two drugs, pirfenidone and nintedanib, have been approved worldwide for prevention of IPF progression. National IPF-registr...

Descripción completa

Detalles Bibliográficos
Autores principales: Pesonen, Ida, Carlson, Lisa, Murgia, Nicola, Kaarteenaho, Riitta, Sköld, Carl Magnus, Myllärniemi, Marjukka, Ferrara, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950183/
https://www.ncbi.nlm.nih.gov/pubmed/29785264
http://dx.doi.org/10.1186/s40248-018-0126-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950183/
https://www.ncbi.nlm.nih.gov/pubmed/29785264
http://dx.doi.org/10.1186/s40248-018-0126-7

Ejemplares similares